---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-077217"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2022-03-16T23:59:59+00:00"
generated_at: "2026-06-26T22:20:26.167396+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apellis reports positive 18-month Phase 3 data for pegcetacoplan in GA; NDA planned Q2 2022

## Summary
- OAKS GA: monthly pegcetacoplan reduced lesion growth 22% (p<0.0001); every-other-month 16% (p=0.0018) at month 18.
- DERBY GA: monthly reduction 13% (p=0.0254); every-other-month 12% (p=0.0332); effects improved vs months 0-6.
- Combined: monthly reduction improved from 13% (months 0-6) to 21% (months 12-18); every-other-month from 12% to 17%.
- Safety: endophthalmitis rate 0.044% per injection; intraocular inflammation 0.23%; no retinal vasculitis or vein occlusion.
- Company plans to submit NDA to FDA for intravitreal pegcetacoplan in GA in Q2 2022.

## SEC filing metadata
- accession: 0001193125-22-077217
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2022-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312522077217/0001193125-22-077217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312522077217/d223867d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-077217
- JSON: https://secwatch.observer/filing/0001193125-22-077217.json
- Plain text: https://secwatch.observer/filing/0001193125-22-077217.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.